Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023
Prevalence of Cannabis Withdrawal Symptoms Among People with Regular or Dependent Use of Cannabinoids
JAMA doi:10.1001/JAMANETWORKOPEN.2020.2370, Bahji, A.,et al, 2020
Psychiatric Illness in Patients with Syncope
Am J Med 99:505-512, Kapoor,W.N.,et al, 1995
Use of Benzodiazepines in Anxiety Disorders
NEJM 328:1398-1405, Shader,R.I.&Greenblatt,D.J., 1993
Attention-Deficit Hyperactivity Disorder in Adults
Clinical Therapeutics 14:138-147, Bellak,L.&Black,R.B., 1992
Acute Neurologic & Psychiatric Complications Associated with Cocaine Abuse
Am J Med 83:841-846, Lowenstein,D.H.,et al, 1987
Benzodiazepines
NEJM 309:354-358, 410-4161983., Greenblatt,D.J.,et al, 1983
Clinicopathologic Conference, Encephalitis due to Behcets Disease
NEJM 387:925-933, Case 27-2022, 2022
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Monoamine Oxidase Inhibitors
Adams & Victors Principles of Neurology Chp 43, pg 1210, Ropper, A.H.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Cocaine
Adams & Victors Principles of Neurology Chp 43, pg 1213, Ropper, A.H.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
The Writing on the Wall
Lancet 372:344, Wilder-Smith,E.P. &Ng,E.S., 2008
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Psychiatric Side Effects During Methysergide Treatment
JNNP 76:1037-1038, Cittadini,E. &Goadsby,P.J., 2005
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Management of Drug and Alcohol Withdrawal
NEJM 348:1786-1795, Kosten,T.R. &O'Connor,P.G., 2003
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Clinical Features and Pharmacologic Treatment of Behavioral Symptoms of Alzheimer's Disease
Neurol 48 (Suppl 6) :S17-S24997., Borson,S.&Raskind,M.A., 1997
Nonmotor Fluctuations in Patients with Parkinson's Disease
Neurol 47:1180-1183, Hillen,M.E.&Sage,J.I., 1996
Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995
Psychiatric Classification of Nonconversion Nonepileptic Seizures
Arch Neurol 52:199-201, Alper,K.,et al, 1995
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
Seizure Disorder
Ciba Clin Symposia 46:4-34, Devinsky,O., 1994
Withdrawal Syndrome after the Double-Blind Cessation of Caffeine Cunsumption
NEJM 327:1109-1114, 11601992., Silverman,R.,et al, 1992
Extrapyramidal side Effects of Antiemetics Presenting as Psychiatric Illness
Gen Hosp Psychiatry 14:192-195, Rodgers,C., 1992
Syncope:Current Diagnostic Evaluation and Management
Ann Int Med 112:850-863, Manolis,A.S.,et al, 1990
"Doom Anxiety"and Delirium in Lidocaine Toxicity
Am J Psychiatry 144:159-163, Saravay,S.M.,et al, 1987
Drug Therapy, Psychotropic Drug Use in the Elderly (First of Two Parts)
NEJM 308:134-138, Thompson,T.L.,et al, 1983
Benzodiazepines
NEJM 29l:l0ll, Nov 1974:29l:l239., Greenblatt,D.J.,et al, 1974